Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINGOLIMOD vs JOENJA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Off-label: chronic inflammatory demyelinating polyneuropathy (CIDP)
Differentiated thyroid cancer (DTC) refractory to radioactive iodine,Renal cell carcinoma (RCC) in combination with everolimus,Hepatocellular carcinoma (HCC) first-line treatment in combination with pembrolizumab
0.5 mg orally once daily
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment.
Primarily metabolized by CYP4F2 via ω-hydroxylation; minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Also undergoes reversible phosphorylation to active metabolite fingolimod-phosphate.
Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8.
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites.
>99.7% bound to human serum albumin; minor binding to lipoproteins.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia).
Vd approximately 1000 L/kg (17,000 L); extensive distribution into tissues, particularly lung, blood cells, and CNS.
Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue.
Oral bioavailability is approximately 93% following a single 5 mg dose; food does not significantly affect absorption.
Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
For Cr Cl 30-60 m L/min: 2.5 mg orally once daily; for Cr Cl <30 m L/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis.
Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Contraindicated.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
For patients 10 years and older weighing >40 kg: 0.5 mg orally once daily. For patients <10 years or ≤40 kg: Not recommended.
Safety and efficacy not established in pediatric patients under 18 years.
No specific dose adjustment; monitor for bradycardia and atrioventricular block due to age-related conduction system changes. Caution in patients ≥65 years due to limited data.
No specific dose adjustment; monitor renal function and adjust dose based on Cr Cl.
Risk of serious infections; cases of fatal herpes infections (e.g., varicella zoster) reported. Requires baseline VZV serology and vaccination if negative.
None.
Bradyarrhythmia and AV block (monitor for 6 hours after first dose), increased infection risk (especially herpes viruses), macular edema (ophthalmologic exam at baseline and 3-4 months after initiation), progressive multifocal leukoencephalopathy (PML), posterior reversible encephalopathy syndrome (PRES), severe exacerbation of MS after discontinuation, respiratory effects (decline in FEV1 and DLCO), liver injury, fetal risk, blood pressure effects (hypertension), and risk of basal cell carcinoma.
Hypertension (including hypertensive crisis),Cardiac dysfunction (reduced LVEF),Arterial thromboembolic events,Hepatic impairment (including hepatotoxicity),Renal impairment (including proteinuria),Hemorrhage,Gastrointestinal perforation or fistula,QT prolongation,Reversible posterior leukoencephalopathy syndrome (RPLS),Thyroid dysfunction,Wound healing complications
Patients with recent myocardial infarction (within 6 months), unstable angina, stroke, transient ischemic attack, decompensated heart failure, or history of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome (unless pacemaker in place), severe active infections, and hypersensitivity to fingolimod or any of its excipients.
None known
Grapefruit juice and Seville oranges may increase drug levels; avoid consumption.
Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk.
FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular septal defects, particularly during the first trimester. Human data are limited, but case reports suggest potential fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation.
First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed.
Fingolimod is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 2:1. Based on a typical maternal dose, the estimated infant exposure is about 0.2-0.4% of the maternal weight-adjusted dose. Due to potential for serious adverse effects (immunosuppression, bradycardia), breastfeeding is not recommended during fingolimod therapy.
Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose.
No specific dose adjustment guidelines exist for fingolimod during pregnancy due to teratogenicity. Pregnancy is a contraindication; discontinue fingolimod before conception or as soon as pregnancy is detected. Pharmacokinetic studies in pregnancy are lacking; no evidence of altered metabolism requiring dose adjustment if used inadvertently.
Due to increased plasma volume and renal clearance during pregnancy, higher doses may be required. Consider dose titration based on therapeutic drug monitoring and clinical response. No specific dose adjustment is established; individualize therapy.
First-dose monitoring required for 6 hours due to bradycardia risk; obtain baseline ECG, CBC, LFTs. Avoid live vaccines; screen for latent infections. Rebound disease activity may occur upon discontinuation; taper not needed but monitor closely.
JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%.
Your heart rate will be monitored for 6 hours after your first dose.,Do not stop fingolimod without consulting your doctor; stopping can cause severe return of MS symptoms.,Avoid grapefruit juice and Seville oranges.,Report any signs of infection, slow heart rate, or visual changes immediately.,Use effective contraception during treatment and for 2 months after stopping.
Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably.,Do not crush, chew, or split tablets; swallow whole.,If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose.,Avoid grapefruit, grapefruit juice, and star fruit during treatment.,Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose.,Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider.
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINGOLIMOD vs JOENJA, answered by our medical review team.
FINGOLIMOD is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.. JOENJA is a Sphingosine 1-Phosphate Receptor Modulator that works by JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINGOLIMOD and JOENJA depend on the specific clinical indication. These are both Sphingosine 1-Phosphate Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINGOLIMOD is: 0.5 mg orally once daily. The standard adult dose of JOENJA is: JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINGOLIMOD and JOENJA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINGOLIMOD is classified as Category C. FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular sept. JOENJA is classified as Category C. First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.